Newron Pharmaceuticals S.p.A.
NP5
Classificação em ações
#17693
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Preço da ação
$10.40
Valor de mercado
$212.64M
Variação (1 dia)
1.09%
Variação (1 ano)
-41.83%
País
IT
Negociar Newron Pharmaceuticals S.p.A. (NP5)
Categoria
Healthcare
Histórico de preços das ações de Newron Pharmaceuticals S.p.A. (NP5)
Preço de fecho mais alto: $10.24 em 2026-10-01
Preço de fecho mais baixo: $31.91 em 2015-07-01
Preço de fecho mais baixo: $31.91 em 2015-07-01
Histórico de preços das ações da Newron Pharmaceuticals S.p.A. de 2015 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2026 (TTM) | -24.57% |
| 2025 | 182.46% |
| 2024 | 72.12% |
| 2023 | 283.57% |
| 2022 | -24.03% |
| 2021 | -24.86% |
| 2020 | -62.21% |
| 2019 | -18.66% |
| 2018 | -28.88% |
| 2017 | -55.22% |
| 2016 | -5.77% |
| 2015 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $535.37 | 25.54% |
US
|
|
| $185.00 | 589.01% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $885.21 | 8.73% |
NL
|
